Structural requirements for the interaction of combretastatins with tubulin: How important is the trimethoxy unit?

Organic and Biomolecular Chemistry

Volumn 1, Issue 17, 2003, Pages 3033-3037

  Gaukroger, Keira ^a   Hadfield, John A ^a,b   Lawrence, Nicholas J ^c,d   Nolan, Steven ^a   McGown, Alan T ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SALFORD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS; BIOCHEMISTRY; MATERIALS TESTING; MOLECULAR DYNAMICS; MOLECULAR STRUCTURE; MOLECULES; PROTEINS; SUBSTITUTION REACTIONS; SYNTHESIS (CHEMICAL); TOXICITY;

COMBRETASTATINS; CYTOTOXICITY; STRUCTURAL REQUIREMENTS; SUBSTITUTED AGENT; TRIMETHOXY UNIT; TUBULIN;

AROMATIC COMPOUNDS;

ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; COMBRETASTATIN; STILBENE DERIVATIVE; TUBULIN;

ANIMAL; ARTICLE; CELL LINE; CELL STRAIN K 562; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; HUMAN; IC 50; IMMUNOHISTOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VERO CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; K562 CELLS; MOLECULAR STRUCTURE; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; VERO CELLS;

EID: 0141518578     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b306878a     Document Type: Article

References (21)

1. J. A. Hadfield, S. Ducki, N. Hirst and A. T. McGown, Prog. Cell Cycle Res., 2003, 5, 309.
2. A. M. Jordan, J. A. Hadfield N. J. Lawrence and A. T. McGown, Med. Res. Rev., 1998, 259-96.
3. M. Cushman, D. Nagarathnam, D. Gopal, H.-M. He, C. M. Lin and E. Hamel, J. Med. Chem., 1992, 35, 2293.
4. M. Cushman, D. Nagarathnam, D. Gopal, A. K. Chakraborti, C. M. Lin and E. Hamel, J. Med. Chem., 1991, 34, 2579.
5. J. A. Hadfield and A. T. McGown, Synth. Commun., 1998, 28, 1421.
6. K. Aleksandrzak, A. T. McGown and J. A. Hadfield, Anti-Cancer Drugs, 1998, 9, 545.
7. J. A. Woods, J. A. Hadfield, A. T. McGown, G. R. Pettit and B. W. Fox, Br. J. Cancer, 1995, 71, 705.
8. R. T. Brown, B. W. Fox, J. A. Hadfield, A. T. McGown, S. P. Mayalarp, G. R. Pettit and J. A. Woods, J. Chem. Soc., Perkin Trans. 1, 1995, 577.
9. A. T. McGown and B. W. Fox, Anti-Cancer Drug Des., 1989, 3, 249.
10. G. M. Tozer, C. Kanthou, C. S. Parkins and S. A. Hill, Int. J. Exp. Pathol., 2002, 83, 21.
11. G. R. Pettit, S. B. Singh, M. R. Boyd, E. Hamel, R. K. Pettit, J. M. Schmidt and F. Hogan, J. Med. Chem., 1995, 38, 1666.
12. G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Pettit and D. J. Chaplin, Cancer Res., 1997, 57, 1829.
13. Z. Getahun, L. Jurd, P. S. Chu, C. M. Lin and E. Hamel, J. Med. Chem., 1992, 35, 1058.
14. J. M. Andreu, B. Perez-Ramirez, M. J. Gorbunoff, D. Ayala and S. N. Timasheff, Biochemistry, 1998, 35, 8356.
15. Q. Shi, K. Chen, S. L. Morris-Natschke and K.-H. Lee, Curr. Pharm. Des., 1998, 4, 219.
16. S. Zhao, J. V. Moore, M. L. Waller, A. T. McGown, J. A. Hadfield, G. R. Pettit and D. L. Hastings, Eur. J. Nucl. Med., 1999, 26, 231.
17. N. J. Lawrence, F. A. Ghani, L. A. Hepworth, J. A. Hadfield, A. T. McGown and R. G. Pritchard, Synthesis, 1999, 1656.
18. K. Gaukroger, J. A. Hadfield, L. A. Hepworth, N. J. Lawrence and A. T. McGown, J. Org. Chem., 2001, 66, 8135.
19. J. Mann in Natural Products Their Chemistry and Biological Significance, Longman, UK, 1984, pp. 419-20.
20. M. E. Watts and M. Woodcock, Eur. J. Cancer, 1992, 28A, 1628.
21. A. Dowlati, K. Robertson, M. Cooney, W. P. Petros, M. Stratford, J. Jesberger, N. Rafie, B. Overmoyer, V. Makkar, B. Stambler, A. Taylor, J. Waas, J. S. Lewin, K. R. McCrae and S. C. Remick, Cancer Res., 2002, 62, 3408.